Viewing Study NCT04544891



Ignite Creation Date: 2024-05-06 @ 3:10 PM
Last Modification Date: 2024-10-26 @ 1:44 PM
Study NCT ID: NCT04544891
Status: COMPLETED
Last Update Posted: 2022-03-22
First Post: 2020-09-09

Brief Title: TREM-1 Pathway Activation in COVID-19
Sponsor: Central Hospital Nancy France
Organization: Central Hospital Nancy France

Study Overview

Official Title: Prognostic Significance of the TREM-1 Pathway Activation in COVID-19
Status: COMPLETED
Status Verified Date: 2022-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: CoviTrem1
Brief Summary: Severe Acute Respiratory Syndrome-Corona Virus-2 infection results in a mild infection in most of the patients However 15-20 require hospitalization and among them 15-20 will develop acute respiratory failure leading to their admission in Intensive Care Unit There are no accepted predictive criteria for aggravation Severe forms of Coronavirus induced disease-19 COVID-19 are the consequence of endotheliopathy and hyperinflammatory and pro-coagulant state The Triggering Receptor Expressed on Myeloid cells-1 TREM-1 is an immunoreceptor that acts as an amplifier of the inflammatory response TREM-1 is expressed on myeloid and endothelial cells Its activation leads to endothelial activation and damage hyperinflammatory and pro-coagulant state TREM-1 activation is associated with poor outcome during septic shock and myocardial infarction

We here aim at investigating the relationship between TREM-1 pathway activation and clinical degradation and outcome of COVID-19 hospitalized patients
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None